Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2013 1
2015 1
2016 2
2017 1
2019 2
2020 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
TP-0903 is active in models of drug-resistant acute myeloid leukemia.
Jeon JY, Buelow DR, Garrison DA, Niu M, Eisenmann ED, Huang KM, Zavorka Thomas ME, Weber RH, Whatcott CJ, Warner SL, Orwick SJ, Carmichael B, Stahl E, Brinton LT, Lapalombella R, Blachly JS, Hertlein E, Byrd JC, Bhatnagar B, Baker SD. Jeon JY, et al. Among authors: orwick sj. JCI Insight. 2020 Dec 3;5(23):e140169. doi: 10.1172/jci.insight.140169. JCI Insight. 2020. PMID: 33268594 Free PMC article.
Evaluation of artemisinins for the treatment of acute myeloid leukemia.
Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD. Drenberg CD, et al. Among authors: orwick sj. Cancer Chemother Pharmacol. 2016 Jun;77(6):1231-43. doi: 10.1007/s00280-016-3038-2. Epub 2016 Apr 28. Cancer Chemother Pharmacol. 2016. PMID: 27125973 Free PMC article.
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.
Elgamal OA, Fobare S, Vibhute S, Mehmood A, Vroom DC, Johnson ML, Stearns B, Lerma JR, Truxall J, Stahl E, Carmichael B, Orwick SJ, Mims AS, Curran E, Santhanam R, Tridandapani S, Phelps MA, Xie Z, Coss CC, Baker SD, Patrick J, Ezzell JK, Rai J, Pan J, Rai SN, Stillwell C, Wunderlich M, Abdulrahim M, Goodwin TE, Hilinski G, Bennett CE, Hertlein E, Byrd JC. Elgamal OA, et al. Among authors: orwick sj. JCI Insight. 2024 Apr 22;9(8):e173646. doi: 10.1172/jci.insight.173646. JCI Insight. 2024. PMID: 38646934 Free PMC article.
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD, Byrd JC. Bhatnagar B, et al. Among authors: orwick sj. Blood Adv. 2023 Aug 22;7(16):4671-4675. doi: 10.1182/bloodadvances.2023010482. Blood Adv. 2023. PMID: 37603350 Free PMC article. No abstract available.
Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.
Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, Zuo Z, Loos WJ, Sparreboom A. Lancaster CS, et al. Among authors: orwick sj. Clin Cancer Res. 2010 Oct 1;16(19):4789-99. doi: 10.1158/1078-0432.CCR-10-1239. Epub 2010 Sep 21. Clin Cancer Res. 2010. PMID: 20858838 Free PMC article.
Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.
Buelow DR, Pounds SB, Wang YD, Shi L, Li Y, Finkelstein D, Shurtleff S, Neale G, Inaba H, Ribeiro RC, Palumbo R, Garrison D, Orwick SJ, Blachly JS, Kroll K, Byrd JC, Gruber TA, Rubnitz JE, Baker SD. Buelow DR, et al. Among authors: orwick sj. Clin Transl Sci. 2019 Nov;12(6):641-647. doi: 10.1111/cts.12669. Epub 2019 Aug 20. Clin Transl Sci. 2019. PMID: 31350825 Free PMC article.
13 results